ES2310206T3 - Derivados de 1-oxa-3,9-diaza-espiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina. - Google Patents

Derivados de 1-oxa-3,9-diaza-espiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina. Download PDF

Info

Publication number
ES2310206T3
ES2310206T3 ES02742943T ES02742943T ES2310206T3 ES 2310206 T3 ES2310206 T3 ES 2310206T3 ES 02742943 T ES02742943 T ES 02742943T ES 02742943 T ES02742943 T ES 02742943T ES 2310206 T3 ES2310206 T3 ES 2310206T3
Authority
ES
Spain
Prior art keywords
formula
diaza
oxa
trifluoromethyl
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02742943T
Other languages
English (en)
Spanish (es)
Inventor
Hai-Ying Cai
Michael Patrick Dillon
Guido Galley
Annick Goergler
Sabine Kolczewski
Dawn Marie Muszynski-Barsy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2310206T3 publication Critical patent/ES2310206T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES02742943T 2001-05-14 2002-05-06 Derivados de 1-oxa-3,9-diaza-espiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina. Expired - Lifetime ES2310206T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111644 2001-05-14
EP01111644 2001-05-14

Publications (1)

Publication Number Publication Date
ES2310206T3 true ES2310206T3 (es) 2009-01-01

Family

ID=8177412

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02742943T Expired - Lifetime ES2310206T3 (es) 2001-05-14 2002-05-06 Derivados de 1-oxa-3,9-diaza-espiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina.

Country Status (17)

Country Link
US (1) US6599900B2 (enExample)
EP (1) EP1390372B1 (enExample)
JP (1) JP4056887B2 (enExample)
KR (1) KR100618063B1 (enExample)
CN (1) CN1264847C (enExample)
AR (1) AR033631A1 (enExample)
AT (1) ATE401333T1 (enExample)
AU (1) AU2002342238B2 (enExample)
BR (1) BR0209604A (enExample)
CA (1) CA2447329C (enExample)
DE (1) DE60227657D1 (enExample)
DK (1) DK1390372T3 (enExample)
ES (1) ES2310206T3 (enExample)
MX (1) MXPA03010321A (enExample)
PT (1) PT1390372E (enExample)
WO (1) WO2002092604A1 (enExample)
ZA (1) ZA200308535B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1716156A2 (en) * 2004-02-10 2006-11-02 F.Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
ES2346147T3 (es) * 2005-03-03 2010-10-11 Janssen Pharmaceutica Nv Derivados de oxa-diaza-espiro-(5.5)-undecanona sustituidos y su uso como antagonistas de las neuroquininas.
NZ556628A (en) 2005-03-08 2009-09-25 Janssen Pharmaceutica Nv Diaza-spiro-[4.4]-nonane derivatives as neurokinin (NK1) antagonists
US7470684B2 (en) 2007-01-03 2008-12-30 Hoffmann-La Roche Inc. Spiropiperidine derivatives as NK3 antagonists
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
BRPI0809646A2 (pt) 2007-03-29 2014-09-23 Hoffmann La Roche Compostod antivirais heterocíclicos
MX375424B (es) 2015-07-31 2025-03-06 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl
MX2019008626A (es) 2017-01-20 2019-09-19 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
JP2020506903A (ja) 2017-01-23 2020-03-05 ファイザー・インク Ｍａｇｌ阻害薬としての複素環式スピロ化合物
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2131021B (en) * 1982-11-24 1985-12-18 Erba Farmitalia Antipsychotic benzoxazines
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
WO1997011940A1 (en) * 1995-09-29 1997-04-03 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation

Also Published As

Publication number Publication date
KR20030094405A (ko) 2003-12-11
US6599900B2 (en) 2003-07-29
BR0209604A (pt) 2004-03-23
CA2447329C (en) 2009-07-28
AU2002342238B2 (en) 2007-01-25
EP1390372A1 (en) 2004-02-25
CN1507449A (zh) 2004-06-23
DE60227657D1 (de) 2008-08-28
CN1264847C (zh) 2006-07-19
KR100618063B1 (ko) 2006-08-30
AR033631A1 (es) 2003-12-26
DK1390372T3 (da) 2008-09-15
US20030004163A1 (en) 2003-01-02
CA2447329A1 (en) 2002-11-21
WO2002092604A1 (en) 2002-11-21
JP2004534758A (ja) 2004-11-18
PT1390372E (pt) 2008-08-25
MXPA03010321A (es) 2004-02-17
JP4056887B2 (ja) 2008-03-05
ATE401333T1 (de) 2008-08-15
EP1390372B1 (en) 2008-07-16
ZA200308535B (en) 2005-01-31

Similar Documents

Publication Publication Date Title
CN115279370B (zh) 用于brd9的靶向降解的化合物
ES2282794T3 (es) Composicion farmaceutica.
ES2296761T3 (es) Derivados de 1,3,8-triaza-espiro(4.5)decan-4-oma como antagonistas receptores de neurocinina.
TW202115062A (zh) Kras突變蛋白抑制劑
CA3202355A1 (en) Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
ES2241891T3 (es) Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b.
ES2430663T3 (es) Compuestos heterocíclicos para el tratamiento de afecciones relacionadas con el estrés
ES2780699T3 (es) Amidas de piperidina fusionadas útiles como moduladores de canales iónicos
ES2392796T3 (es) Moduladores de tipo indol del receptor nicotínico de acetilcolina alfa-7
CN111278815A (zh) 戊二酰亚胺
ES2238560T3 (es) Derivados de piperidina como antagonistas de neuroquinina 1.
EA013108B1 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
SI9400091A (en) Substituted pyrrolo(2,3-b)pyridine derivatives
PT1638970E (pt) Derivados de pirid(2,1-a)isoquinolina como inibidores de dpp-iv
ES2251512T3 (es) Derivados de quinazolina como antagonista adrenergicos alfa-1.
PT1720859E (pt) Antagonistas do receptor de quimiocina
WO1999032489A1 (en) Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO2008091021A1 (ja) ヘテロシクリデン－ｎ－（アリール）アセトアミド誘導体
CA3003559C (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
KR20020073493A (ko) 치환된 피페리딘, 당해 화합물을 함유하는 약제 및 이의제조방법
JPH0568474B2 (enExample)
ES2271327T3 (es) Antagonistas heterobiciclicos de crf.
WO1997016192A1 (en) Muscarine antagonists
EP1390372B1 (en) 1-oxa-3,9-diaza-spiro'5,5]undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor
AU2002342238A1 (en) 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor